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Abstract
The presence of cell-free microRNAs (miRNAs) has been detected in a range of body fluids. The miRNA content of plasma/
serum in particular has been proposed as a potential source of novel biomarkers for a number of diseases. Nevertheless, the
quantification of miRNAs from plasma or serum is made difficult due to inefficient isolation and lack of consensus regarding
the optimal reference miRNA. The effect of haemolysis on the quantification and normalisation of miRNAs in plasma has not
been investigated in great detail. We found that levels of miR-16, a commonly used reference gene, showed little variation
when measured in plasma samples from healthy volunteers or patients with malignant mesothelioma or coronary artery
disease. Including samples with evidence of haemolysis led to variation in miR-16 levels and consequently decreased its
ability to serve as a reference. The levels of miR-16 and miR-451, both present in significant levels in red blood cells, were
proportional to the degree of haemolysis. Measurements of the level of these miRNAs in whole blood, plasma, red blood
cells and peripheral blood mononuclear cells revealed that the miRNA content of red blood cells represents the major
source of variation in miR-16 and miR-451 levels measured in plasma. Adding lysed red blood cells to non-haemolysed
plasma allowed a cut-off level of free haemoglobin to be determined, below which miR-16 and miR-451 levels displayed
little variation between individuals. In conclusion, increases in plasma miR-16 and miR-451 are caused by haemolysis. In the
absence of haemolysis the levels of both miR-16 and miR-451 are sufficiently constant to serve as normalisers.
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Introduction
MicroRNAs (miRNAs), a class of 18–25 nt long non-coding
RNAs, are post-transcriptional modulators of gene expression [1–
3]. They are involved in the regulation of normal physiological
processes and there is rapidly increasing evidence that they also
play a prominent role in cancer [2,4,5] and non-malignant
conditions such as heart disease [6]. Recently a number of studies
have shown that miRNAs are readily detectable in body fluids,
and the presence of specific miRNA patterns in plasma of diseased
(cancer) patients has raised the possibility of their use as
biomarkers [7–9]. MiRNAs in plasma/serum seem to be more
stable than mRNA and this has been attributed to their
encapsulation into microvesicles [10,11]. More recently, associa-
tion of extracellular miRNAs with nucleophosmin [12], argonaute
2 [13,14] and high density lipoproteins [15] has been demon-
strated, suggesting alternative mechanisms of miRNA export and
transport in the circulatory system.
Since the first reports revealing the presence of miRNAs in
plasma and serum, numerous studies have identified distinct
miRNA expression patterns associated with disease and have
proposed them as candidate biomarkers [9]. However, when
comparing the methods applied in different studies, a consensus on
the best methods for the measurement and accurate quantification
of disease-related miRNA patterns in body fluids has yet to be
reached.
When developing miRNAs as biomarkers one of the first issues
to consider is that each body fluid appears to have a normal
spectrum of miRNAs [8], presumably a reflection of normal
physiology. MiRNAs in plasma and serum are thought to
contribute to the (normal) functioning of the circulatory and the
immune system [16,17]. Moreover, different blood cell compo-
nents seem to be characterised by a distinct miRNA profile. While
red blood cells (RBCs) contain high levels of miR-451 and miR-16,
these miRNAs, which are thought to play a role in erythropoiesis
[16,18], were found at low levels in leucocytes and platelets
[19,20]. MiRNAs in blood may also be present in cell-derived
microvesicles, exosomes and apoptotic bodies, which seem to
shuttle specific subsets of miRNAs to recipient cells [21–23].
The measurement and exact quantification of miRNA are
further hampered by the low yields of RNA in serum or plasma,
complicating normalisation strategies that are based on quantifi-
cation of total RNA. One of the most frequently used strategies to
overcome this problem when quantifying miRNAs is the use of a
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commonly expressed mRNA, miRNA or other small RNA.
A number of groups have proposed the use of a stably expressed
miRNA such as miR-16 or the small nucleolar RNA RNU6B as a
normaliser [24–27], but others have reported significant variation
in the levels of these normalisers [28,29]. This has led to the
adoption of normalisation strategies based on the detection/
quantification of ‘spiked in’ synthetic miRNAs [30–32]. Since
miR-16 is one of the most abundant miRNAs present in RBCs
[20], we theorised that haemolysis may be responsible for
increasing levels of this candidate reference gene.
In this study we assessed the variation of miR-16 levels in
plasma samples from healthy individuals, patients with malignant
mesothelioma (MM) and coronary artery disease (CAD). We
found comparable miR-16 levels in the different groups of
samples, but only in the absence of haemolysis. Only in plasma
samples with a haemoglobin content equivalent to an absorbance
of less than 0.2 at 414 nm were the levels of miR-16 similar
enough to be suitable for normalisation.
Results
Plasma miR-16 levels show little variation between
individuals with different physiological conditions
Investigating the variation of a number of potential reference
genes we found that while four moderately abundant miRNAs,
hsa-miR-16, -15b, -24 and -451 were readily detectable in plasma
samples the small nucleolar RNA RNU6B could not be detected
in any sample (data not shown). Levels of the four miRNAs were
compared in the plasma (without obvious signs of haemolysis) of
nine healthy volunteers, eighteen patients with MM and ten
patients with CAD. While the Cq (quantification cycle) values for
miR-15b and -24 varied between healthy and diseased individuals,
those of miR-451 showed less variation and those of miR-16
varied by only 2 cycles (Figure 1A). Furthermore, measurements of
miR-16 levels in plasma obtained at three separate occasions from
the same individual varied by less than 1 cycle (Figure 1B).
Presence of haemolysis in plasma samples affects levels
of miR-16 and miR-451
After processing of blood samples, the plasma in some of the
tubes exhibited the characteristic pink discolouration as seen with
haemolysis. As it is known that miR-451 and miR-16 are
abundantly present in RBCs, we separately analysed normal and
discoloured (pink) samples from the same collection. Samples that
were considered to be haemolysed due to pink discolouration
indeed showed increased absorbance at 414, 541 and 576 nm
(Figure 2A) confirming the presence of free haemoglobin [33]. In
the haemolysed samples the concentration of both miR-451 and
miR-16 was significantly higher (Figure 2B), with an increase in
absolute copy number per ml plasma of up to 8-fold as compared
with non-haemolysed samples.
RBCs represent the major source of miR-16 and miR-451
in whole blood
Measurement of both miR-451 and miR-16 levels in whole
blood as well as RBCs, peripheral blood mononuclear cells
(PBMCs) and plasma separated by Ficoll-Paque revealed that
RBCs represent the most likely source of variation in levels of these
miRNAs in plasma/serum. The number of copies of both miR-
451 and miR-16 in (whole) blood mainly derived from RBCs,
while PBMCs and plasma were found to contribute less than 1%
of copies of both miRNAs (Table 1).
Determination of a threshold of free haemoglobin below
which levels of erythrocyte miRs display little variability
While gross haemolysis can be identified easily by change in
colour of the plasma, we theorised that an increase of miRNA
levels might occur even before noticeable colour change of the
supernatant plasma. To investigate the effect of haemolysis on the
levels of miRNAs we artificially introduced haemolysis by serially
diluting lysed RBCs in non-haemolysed plasma from a healthy
donor. While a change in plasma colour due to haemolysis was
only visible when the RBC concentration exceeded 0.125% (v/v),
the absorbance of the main haemoglobin related peak at 414 nm
increased above background from a RBC concentration of as little
as 0.016% (Figure 3). This increase in lambda 414 absorption
correlates with an increase in free haemoglobin concentration
(mg/dL) as well as the levels of LDH in the samples. In contrast
the other potential indicators of haemolysis, ALT and AST, were
only significantly increased in samples with visible haemolysis
(Table S1). The level of the RBC-enriched miRNAs miR-451 and
miR-16 increased with increasing percentage of free haemoglobin.
With as little as 0.031% (v/v) RBCs added to plasma, a
concentration at which haemolysis of the sample was visually
not apparent, the number of copies/ml plasma was higher than the
mean miR-16 level detected in 25 non-haemolysed samples
(1.12610
660.49610
6 copies/ml plasma). Levels of miR-15b also
increased with haemolysis, but at much lower absolute levels,
Figure 1. Variation in levels of endogenous miRs in plasma. (A)
Levels of miRs 15b, 16, 24 and 451 were measured in plasma from MM
or CAD patients or healthy controls (n=37) by RT-qPCR. (B) Variation of
miR-16 levels in three individual samples (independent sampling
occasions) from three volunteers (#1–3). The lines within boxes
represent the median, the horizontal borders of each box represent
the 25
th and 75
th percentile, and the limits of the vertical lines represent
the maximum and minimum Cq.
doi:10.1371/journal.pone.0024145.g001
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haemolysis (Figure S1A). Measurement of three more miRNAs
present at moderate levels in plasma showed that while miR-92a
levels also increases with the degree of haemolysis those of miR-
155 and miR-625* remained stable (Figure S1B).
Analysing our series of haemolysed and non-haemolysed plasma
samples (9 healthy, 20 MM and 16 CAD), we further assessed the
levels of all four miRNAs. We found that using an absorbance at
414 nm of higher than 0.2 as cut-off to distinguish haemolysed and
non-haemolysed plasma (Figure 4A, p,0.001) significantly
decreased the variability in both miR-451 (Figure 4B, p=0.008)
and miR-16 (Figure 4C, p=0.026) levels. Exclusion of haemolysed
plasma did not reduce the variability in miR-15b (Figure 4D,
p=0.893) and miR-24 (Figure 4E, p=0.086) levels.
Effect of haemolysis on potential miRNA biomarkers for
CAD
To investigate the effect of haemolysis on miRNAs proposed as
biomarkers, we measured levels of miR-92a and miR-155, two
miRNAs previously shown to be present at lower levels in the
plasma of CAD patients than in healthy controls. The levels of
miR-92a were also elevated in haemolysed plasma of two MM, 1
CAD patient and 1 healthy control compared with matched non-
haemolysed samples from the same individuals. In contrast to
miR-16 and miR-451, however, the increase in miR-92a
calculated by using the 2
2DCq [34] method did not seem to
correlate with the degree of haemolysis (Figure 5A). In contrast to
miR-92a, the levels of miR-155 were only increased in two out of
four haemolysed samples (Figure 5A). Quantification of miRNA
Figure 2. Correlation between degree of haemolysis and levels of miRNAs in plasma. Levels of free haemoglobin as well as miR-16 and -
451 were measured in matching haemolysed and non-haemolysed plasma samples from different EDTA tubes of the same blood collection from four
different patients. (A) Characteristic Soret bands of free haemoglobin occur at 414, 541 and 576 nm. (B) The increase in free haemoglobin in
haemolysed compared to non-haemolysed plasma correlates with fold increase in levels of both miR-451 and miR-16 as measured by RT-qPCR. Values
are normalised to non-haemolysed samples. MM1, MM2, CAD1, N1=Pairs of haemolysed and non-haemolysed plasma from four patients/controls.
doi:10.1371/journal.pone.0024145.g002
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2DDCq [34] method with normalisation to miR-16
resulted in lower miRNA levels in haemolysed than in non-
haemolysed samples (Figure 5B), although the measurement in the
dilution series (Figure S1B) showed a correlation between the
degree of haemolysis and miR-92a levels. Similar results were also
obtained for measurement of miR-15b and miR-24 in the same
samples (data not shown).
Discussion
A number of recent studies have shown that miRNAs are
detectable in a variety of body fluids and miRNAs in plasma and
serum have attracted particular attention as candidate biomarkers
for a range of diseases [9]. However, although miRNAs are readily
detectable in both plasma and serum, the identification of disease-
specific miRNAs or miRNA expression patterns is complicated by
the fact that the majority of miRNAs in blood do not seem to be
affected by the presence of disease. Studies profiling the miRNA
content of normal serum have for example shown that there is
extensive overlap between the miRNA profiles of serum and blood
cells, suggesting a physiological role for these miRNAs [28,35].
Detailed studies have provided evidence that miR-451 and miR-
16 are involved in the late stages of erythropoiesis, and that miR-
451 is erythroid specific [18,20]. In contrast, miR-155 was found
at higher levels in platelets and B/T lymphocytes, and miR-223
was found in high levels in granulocytes and monocytes, suggesting
that they play a role in the differentiation of these cell types
[16,20,36].
In addition to miRNAs present in different blood cell types, the
contents of microvesicles represent another source for both normal
and disease-specific miRNAs found in the circulation. Microves-
icles (MVs) are released by normal cells including haematopoietic
lineages [22,23,35], and are thought to act as a shuttle to deliver
nucleic acids, including miRNAs, to recipient cells [22,23].
Furthermore it was shown that MVs released by tumour cells
contain cancer-specific miRNA signatures that differentiate them
from MVs released by normal cells [37,38]. Comparisons between
cellular and exosomal miRNA content also showed that several
miRNAs can be found in higher concentrations in exosomes than
in the corresponding tumour cell, suggesting selective packaging of
miRNAs into exosomes [22].
Figure 3. Relationship between free haemoglobin and miRNA content of plasma samples. A dilution series of lysed RBCs in plasma (top)
was prepared and haemoglobin content measured by absorbance at 414 nm [33]. RNA was isolated from the samples indicated by the box and levels
of miR-16 and miR-451 were quantified using a standard curve. While a change in plasma colour is only clearly visible from a RBC concentration of
0.125% (v/v) the amount of free haemoglobin as well as this of both miR-451 and miR-16 already substantially increased at a RBC concentration of
0.031% (v/v).
doi:10.1371/journal.pone.0024145.g003
Table 1. Levels of miR-16 and miR-451 in different fractions
of blood.
Hsa-miR-16 Hsa-miR-451
Whole blood 1.15E+12 1.09E+12
RBCs 1.09E+12 1.03E+12
PBMCs 2.19E+06 2.23E+04
Plasma 6.32E+08 8.38E+08
MiRNAs were isolated and quantified from either whole blood or different
blood fractions separated by Ficoll gradient. Copy numbers per milliliter whole
blood were calculated for each miRNA based on a standard curve generated
using synthetic oligonucleotides with sequences corresponding to the mature
miRNA sequence.
doi:10.1371/journal.pone.0024145.t001
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high protein content and low RNA concentrations of plasma/
serum. Even with the use of carrier molecules to improve isolation
[39,40], yields are often at or below the threshold for accurate
quantification by spectrophotometric analyses [41]. The low yields
of RNA extracted from plasma make a quantification of miRNAs
in copies per nanogram total RNA difficult. These problems are
not unique to plasma or serum. A recent study evaluating the use
of different reference RNAs for a range of tissue samples has
shown that normalisation to total RNA input is highly unstable
[42]. An additional argument against the use of total RNA as a
normaliser is the observation that the total plasma/serum RNA
content may change (increase) with disease state [43].
A frequently used alternative approach for normalisation is the
use of a ubiquitously expressed RNA or miRNA as reference gene.
While the small nucleolar RNA RNU6B is often used for
normalisation when quantifying miRNAs from tissue samples
[44,45], levels of this small RNA were found to be variable in a
significant number of studies [25,26,28,35,46]. A range of miRNA
candidates for normalisation has also been evaluated, with miR-16
the most frequently used. However, while some studies showed that
miR-16 was present at similar levels in samples from healthy
individuals and diseased patients [25–27,47], other studies suggest-
ed that miR-16 levels were not consistent enough to be used for
normalisation [28,29]. We have shown that the plasma levels of
miR-16 from healthy controls as well as patients with either MM or
CAD were very similar (Figure 1A). The low coefficient of variance
of miR-16 in individuals with and without disease, together with the
observation that the levels of miR-16 in plasma taken at separate
occasions from the same individual varied by less than one Cq in
RT-qPCR (Figure 1B) strengthen our conclusion that miR-16 levels
can serve as a reference for normalisation.
Figure 4. Determination of a cut-off level of free haemoglobin to distinguish haemolysed from non-haemolysed plasma. Levels of
free haemoglobin, miR-451, -16, -15b and -24 were measured in a cohort of non-haemolysed (circles, n=23) and haemolysed (squares, n=22) plasma
samples from healthy volunteers and MM or CAD patients. Applying a cut-off at an absorbance at 414 nm of higher than 0.2 (A) to remove
haemolysed samples from the analysis significantly decreased the variability for both miR-451 (B) and miR-16 (C), and showed that in non-
haemolysed samples miR-16 and miR-451 levels showed little variation in samples from individuals with different physiological conditions. In contrast
the variability of miR-15b (D) and miR-24 (E) levels was not reduced by exclusion of haemolysed samples. * p,0.05.
doi:10.1371/journal.pone.0024145.g004
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different components showed that the level of both miRNAs in
whole blood are dominated by the miRNA content of red blood
cells and that only a fraction is derived from plasma or PBMCs
(,1%). Thus the increase in miR-16 levels is likely to be caused by
rupture of RBCs. In vitro haemolysis is a relatively common
phenomenon during collection of blood. Occasionally, when
multiple tubes from the same sampling were separated, both
haemolysed and non-haemolysed plasma were obtained. Using
non-haemolysed and haemolysed plasma isolated from the same
collection we were able to show that levels of both miR-451 and
miR-16 in plasma increased with the degree of haemolysis
(Figure 2). These data are in line with a recent study showing
that the levels of certain miRNAs, such as miR-16 can vary with
haemolysis [48]. Using a dilution series of RBCs in plasma, we
confirmed that the levels of both miRNAs were already
significantly increased before a change in plasma colour from
yellow to pink was visible (Figure 3), while other miRs such as
miR-24 and miR-155 remained unchanged (Figure S1). Applying
these data to a series of control and patient samples with different
degrees of haemolysis we found that using a cut-off level based on
measurement of free haemoglobin allowed us to distinguish
between non-haemolysed and haemolysed plasma. Removing
haemolysed samples resulted in significantly decreased variance in
levels of both miR-451 and miR-16 (Figure 4).
A number of studies have investigated the potential use of
miRNAs, including miRs-92a and -155, as plasma biomarkers of
heart disease [24,31,49–51]. MiR-92a is a member of the miR-
17,92 cluster of regulators of angiogenesis with expression
predominantly in endothelial cells [52,53], whereas miR-155 was
found to be highly expressed in platelets as well as being involved
in maturation of B and T cells [16,20,36].
Comparing levels of miR-92a and miR-155 in non-haemolysed
and haemolysed plasma collected from patients revealed that, like
miR-16 and miR-451, the absolute levels of miR-92a are increased
in haemolysed plasma. In contrast only half of the haemolysed
samples showed an increase in miR-155. Most importantly,
however, the magnitude of increases in miR-92a and miR-155, as
Figure 5. Levels of potential biomarkers for CAD in haemolysed and non-haemolysed plasma. Levels of miR-92a and 155 were measured
in matching haemolysed and non-haemolysed plasma samples from different EDTA tubes of the same blood collection from three different MM or
CAD patients and 1 healthy control. (A) The increases in miRNA levels in haemolysed plasma as compared to non-haemolysed plasma, without
normalisation to miR-16 calculated using 2
2DCq.( B) Changes in miR-92a and miR-155 levels in haemolysed plasma when calculated using the 2
2DDCq
method with miR-16 as reference. MM1, MM2, CAD1, N1=Pairs of haemolysed and non-haemolysed plasma from four patients/controls.
doi:10.1371/journal.pone.0024145.g005
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and miR-451. This has implications for quantification via the
2
2DDCq method, especially when haemolysed samples are used.
Applying 2
2DDCq with miR-16 as normalising reference (Figure 5B)
falsely suggested that both miR-92a and miR-155 were present at
lower levels in haemolysed than in non-haemolysed plasma taken
during the same sampling from the same patient. This discrepancy
highlights that a change in miR-16 and miR-451 levels due to even
minimal haemolysis makes these miRNAs inappropriate for use as
normalisers between samples.
The measurement of miRNAs in plasma or serum is a young
and quickly evolving field. Besides a necessity for a consistent and
optimised RNA isolation procedure, the strategy applied for
normalisation of plasma miRNA levels represents a crucial step in
accurate quantification. We and others have shown that miR-16,
the most commonly used reference miRNA, is present at similar
levels in plasma from healthy controls and patients with different
diseases. However, our finding that haemolysis can significantly
affect the levels of plasma miRNAs has implications for the use of
miR-16 as normaliser. Low-level haemolysis during the collection
of plasma samples is a frequently occurring event which increases
the plasma levels of RBC-derived miRNAs. It also has the
potential to influence the measurement of any candidate miRNA
biomarker(s) that is also present in RBCs. This suggests that the
measurement of free haemoglobin in plasma samples might be a
simple test method to determine whether a sample is suitable for
miRNA analysis using a normalisation strategy based on an
endogenous miRNA.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki and was specifically approved by the
Sydney Local Health Network, Human Research Ethics Com-
mittees based at Concord Repatriation General Hospital and
Royal Prince Alfred Hospital. All samples were collected from
individuals who had given written informed consent for this study.
Blood collection
Peripheral blood samples were collected from the antecubital
fossa into one to three 4 ml or 10 ml Vacutainer Plus K3EDTA
tubes (BD Biosciences) using a butterfly device (21G). Samples
from healthy volunteers were collected on three separate
occasions, while blood from patients with either MM or CAD
was collected prior to treatment. Within 30 min of blood
collection, the tubes were centrifuged for 20 min at 2500 g at
room temperature. Plasma and RBCs were stored at 280uC until
further processing. PBMCs were separated from whole blood
using Ficoll-Paque PLUS (GE Healthcare) according to the
manufacturer’s protocol and processed further immediately.
RBC lysate was prepared by immediately freezing the RBC pellet
after centrifugation at 280uC. Prior to use the thawed RBC
samples were then mixed vigorously using a vortex to increase cell
lysis.
Synthetic RNAs
Synthetic RNAs corresponding in sequence to the mature
sequences of hsa-miR-16,hsa-miR-451, hsa-miR-15b and hsa-
miR-24 were synthesised by Integrated DNA Technologies.
RNA isolation
Total RNA was isolated using the mirVana PARIS miRNA
isolation kit (Ambion/Applied Biosystems) according to the
manufacturer’s instructions for isolation of total RNA, with the
addition of a second phenol-chloroform extraction of the aqueous
phase obtained after the first extraction to aid in removal of the
high protein content. Following the denaturing step, 100 mgo f
mussel glycogen (Roche) was added as carrier to aid RNA
isolation. Isolated RNA eluted in 100 mlH 2O was quantified using
a Nanophotometer (Implen) with readings at 260 and 280 nm.
RNA samples were stored at 280uC until further processing.
Real-time RT-qPCR
Quantification of miRNA content in RNA from plasma was
performed using stem-loop primers for reverse transcription and
TaqMan primers/probe specific for each miRNA (Applied
Biosystems, see Table S2 for TaqMan Assay IDs). For reverse
transcription we used the TaqMan MicroRNA Reverse Tran-
scription Kit (Applied Biosystems) with the following reaction
conditions: 30 min at 16uC, followed by 30 min at 42uC and
5 min at 85uC. For each plasma sample the reaction was carried
out in a total reaction volume of 5 ml with a fixed volume of
1.67 ml isolated RNA as template.
For absolute quantification of miRNAs we generated standard
curves using synthetic RNAs (Integrated DNA Technologies)
corresponding in sequence to the mature miRNAs detected. A
dilution series of these synthetic RNAs ranging from 10
9 to 10
4
miRNA copies per qPCR reaction was generated in the presence
of 1 ng/ml yeast tRNA (Roche). The reverse transcriptions for the
standard curves were performed in a total reaction volume of 10 ml
with 2.96 ml of a synthetic miRNA solution of appropriate
concentration using the same reaction conditions as for the
plasma samples. All cDNA was used immediately in qPCR
reactions or stored at 220uC for use within one week.
Following reverse transcription, as recommended by the
manufacturer, the cDNA was further diluted by addition of
28.9 mlH 2O in order to achieve a final dilution of 1:15 of the RT
product. 2.25 ml of the diluted RT product were then used as
template in a triplicate qPCR with a total reaction volume of
10 ml. Amplification was performed using miRNA TaqMan
primers/probe specific for each miRNA together with TaqMan
26 Universal PCR MasterMix, No AmpErase UNG (Applied
Biosystems) with enzyme activation for 10 min at 95uC followed
by 40 cycles of 15 s at 95uC and 60 s at 60uC. For generation of
standard curves, the RT product was diluted 1:10 in H2O and
2.25 ml of this dilution were used as template. No template and no
RT samples were included as negative controls. The qPCR
reactions were set up manually and run on a Stratagene Mx3000P
instrument. Cq (quantification cycle) values were determined using
adaptive-baseline and background-based threshold (cycle-range 5–
8) using the MxPro Mx3000P v4.10 software (Stratagene).
Relative levels of miRNAs in haemolysed and non-haemolysed
plasma (Figure 5) were calculated using either the 2
2DCq or the
2
2DDCq method [34]. Briefly, in case of 2
2DCq (Figure 5A) DCq
was calculated for each miR by subtracting the Cq of the non-
haemolysed samples from its matching haemolysed value. For
2
2DDCq calculations for each sample the first DCq was calculated
by subtracting the miR-16 value from the Cq of the miR of
interest. The DCq of the non-haemolysed sample was then
subtracted from that of its matching haemolysed sample.
Haemoglobin measurement
Levels of free haemoglobin in the plasma samples were
measured by spectral analysis [33]. Absorbance peaks at 414,
541 and 576 nm were indicative of free haemoglobin, with higher
absorbance in samples with higher degree of haemolysis.
Haemolysis Alters miRNA Content of Plasma
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Differences in variability of expression levels were analysed
using Levene’s test for equality of variances. P-values are
unadjusted and a value of #0.05 was considered significant.
Analyses were conducted using PASW statistics 18 software.
Supporting Information
Figure S1 Relationship between free haemoglobin and miRNA
content of plasma samples. (A) Levels of miR-15b and miR-24 in
plasma samples from the RBC dilution series were quantified
using a standard curve. While levels of miR-15b increased with the
degree of haemolysis, those of miR-24 remained similar in all
samples. (B) Changes in raw Cq values of miR-92a, miR-155 and
miR-625* in samples from the same dilution series. Only miR-92a
levels changed with increased haemolysis.
(TIF)
Table S1 Measurement of additional potential markers of
haemolysis in the RBCs in plasma dilution series. Levels of
LDH, ALT and AST and the concentration of haemoglobin in
mg/dL in the samples of the dilution series were measured in the
Diagnostic Pathology Unit, Concord Repatriation General
Hospital, Sydney, using the Roche Modular System.
(DOC)
Table S2 miRNA TaqMan assays used in this study.
(DOC)
Acknowledgments
We thank Peter Forrest and Dorothy Kouzios from the Diagnostic
Pathology Unit of Concord Repatriation General Hospital in Sydney for
analysing additional markers of haemolysis. We further thank our
colleagues for helpful discussions and critical evaluation of the manuscript.
Author Contributions
Conceived and designed the experiments: MBK GR. Performed the
experiments: MBK. Analyzed the data: MBK NJA GR. Contributed
reagents/materials/analysis tools: SCK JJE MPV. Wrote the paper: MBK
NvZ GR.
References
1. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 116: 281–297.
2. Lee YS, Dutta A (2009) MicroRNAs in cancer. Annu Rev Pathol 4: 199–227.
3. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by
adenosines, indicates that thousands of human genes are microRNA targets. Cell
120: 15–20.
4. Garzon R, Calin GA, Croce CM (2009) MicroRNAs in Cancer. Annu Rev Med
60: 167–179.
5. Ma J, Dong C, Ji C (2010) MicroRNA and drug resistance. Cancer Gene Ther
17: 523–531.
6. Small EM, Olson EN (2011) Pervasive roles of microRNAs in cardiovascular
biology. Nature 469: 336–342.
7. Hanson EK, Lubenow H, Ballantyne J (2009) Identification of forensically
relevant body fluids using a panel of differentially expressed microRNAs. Anal
Biochem 387: 303–314.
8. Weber JA, Baxter DH, Zhang S, Huang DY, How Huang K, et al. (2010) The
MicroRNA Spectrum in 12 Body Fluids. Clin Chem 56: 1733–1741.
9. Reid G, Kirschner MB, van Zandwijk N (2010) Circulating microRNAs:
association with disease and potential use as biomarkers. Crit Rev Oncol
Hematol doi:10.1016/j.critrevonc.2010.11.004.
10. Cortez MA, Calin GA (2009) MicroRNA identification in plasma and serum: a
new tool to diagnose and monitor diseases. Expert Opin Biol Ther 9: 703–711.
11. Kosaka N, Iguchi H, Ochiya T (2010) Circulating microRNA in body fluid: a
new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101:
2087–2092.
12. Wang K, Zhang S, Weber J, Baxter D, Galas DJ (2010) Export of microRNAs
and microRNA-protective protein by mammalian cells. Nucleic acids research
38: 7248–7259.
13. Turchinovich A, Weiz L, Langheinz A, Burwinkel B (2011) Characterization of
extracellular circulating microRNA. Nucleic acids research.
14. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, et al. (2011)
Argonaute2 complexes carry a population of circulating microRNAs indepen-
dent of vesicles in human plasma. Proc Natl Acad Sci U S A 108: 5003–5008.
15. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT (2011)
MicroRNAs are transported in plasma and delivered to recipient cells by high-
density lipoproteins. Nature cell biology 13: 423–433.
16. Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J (2010)
The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol
84: 1–16.
17. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF (2007) miR-150, a microRNA
expressed in mature B and T cells, blocks early B cell development when
expressed prematurely. Proc Natl Acad Sci U S A 104: 7080–7085.
18. Bruchova H, Yoon D, Agarwal AM, Mendell J, Prchal JT (2007) Regulated
expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp
Hematol 35: 1657–1667.
19. Ramkissoon SH, Mainwaring LA, Ogasawara Y, Keyvanfar K, McCoy JP, Jr.,
et al. (2006) Hematopoietic-specific microRNA expression in human cells. Leuk
Res 30: 643–647.
20. Merkerova M, Belickova M, Bruchova H (2008) Differential expression of
microRNAs in hematopoietic cell lineages. Eur J Haematol 81: 304–310.
21. Collino F, Deregibus MC, Bruno S, Sterpone L, Aghemo G, et al. (2010)
Microvesicles derived from adult human bone marrow and tissue specific
mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS One 5:
e11803.
22. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, et al. (2007) Exosome-
mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic
exchange between cells. Nat Cell Biol 9: 654–659.
23. Wang K, Zhang S, Weber J, Baxter D, Galas DJ (2010) Export of microRNAs
and microRNA-protective protein by mammalian cells. Nucleic Acids Res.
24. Ai J, Zhang R, Li Y, Pu J, Lu Y, et al. (2010) Circulating microRNA-1 as a
potential novel biomarker for acute myocardial infarction. Biochem Biophys Res
Commun 391: 73–77.
25. Huang Z, Huang D, Ni S, Peng Z, Sheng W, et al. (2010) Plasma microRNAs
are promising novel biomarkers for early detection of colorectal cancer.
Int J Cancer 127: 118–126.
2 6 . L a w r i eC H ,G a lS ,D u n l o pH M ,P u s h k a r a nB ,L i g g i n sA P ,e ta l .( 2 0 0 8 )
Detection of elevated levels of tumour-associated microRNAs in serum of
patients with diffuse large B-cell lymphoma. Br J Haematol 141: 672–
675.
27. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, et al. (2010)
Circulating microRNAs as novel minimally invasive biomarkers for breast
cancer. Ann Surg 251: 499–505.
28. Chen X, Ba Y, Ma L, Cai X, Yin Y, et al. (2008) Characterization of
microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res 18: 997–1006.
29. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, et al. (2009) Differential
expression of microRNAs in plasma of patients with colorectal cancer: a
potential marker for colorectal cancer screening. Gut 58: 1375–1381.
30. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008)
Circulating microRNAs as stable blood-based markers for cancer detection. Proc
Natl Acad Sci U S A 105: 10513–10518.
31. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, et al. (2010) Circulating microRNA:
a novel potential biomarker for early diagnosis of acute myocardial infarction in
humans. Eur Heart J 31: 659–666.
32. Wang JF, Yu ML, Yu G, Bian JJ, Deng XM, et al. (2010) Serum miR-146a and
miR-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun
394: 184–188.
33. Wong CH, Song C, Heng KS, Kee IH, Tien SL, et al. (2006) Plasma free
hemoglobin: a novel diagnostic test for assessment of the depth of burn injury.
Plast Reconstr Surg 117: 1206–1213.
34. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:
402–408.
35. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, et al. (2008) Detection of
microRNA expression in human peripheral blood microvesicles. PLoS One 3:
e3694.
36. Tili E, Croce CM, Michaille JJ (2009) miR-155: on the crosstalk between
inflammation and cancer. Int Rev Immunol 28: 264–284.
37. Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, et al. (2010) Selective
release of microRNA species from normal and malignant mammary epithelial
cells. PLoS One 5: e13515.
38. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, et al. (2008)
MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26:
462–469.
39. Andreasen D, Fog JU, Biggs W, Salomon J, Dahslveen IK, et al. (2010)
Improved microRNA quantification in total RNA from clinical samples.
Methods 50: S6–9.
Haemolysis Alters miRNA Content of Plasma
PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e2414540. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA,
Hopmans ES, et al. (2010) Functional delivery of viral miRNAs via exosomes.
Proc Natl Acad Sci U S A 107: 6328–6333.
41. Kroh EM, Parkin RK, Mitchell PS, Tewari M (2010) Analysis of circulating
microRNA biomarkers in plasma and serum using quantitative reverse
transcription-PCR (qRT-PCR). Methods 50: 298–301.
42. Peltier HJ, Latham GJ (2008) Normalization of microRNA expression levels in
quantitative RT-PCR assays: identification of suitable reference RNA targets in
normal and cancerous human solid tissues. RNA 14: 844–852.
43. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH (2009)
Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer
10: 42–46.
44. Choong ML, Yang HH, McNiece I (2007) MicroRNA expression profiling
during human cord blood-derived CD34 cell erythropoiesis. Exp Hematol 35:
551–564.
45. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY (2007)
MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control
of cell proliferation and adhesion-independent growth. Cancer Res 67:
8433–8438.
46. Zhu W, Qin W, Atasoy U, Sauter ER (2009) Circulating microRNAs in breast
cancer and healthy subjects. BMC Res Notes 2: 89.
47. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, et al. (2009) The
detection of differentially expressed microRNAs from the serum of ovarian
cancer patients using a novel real-time PCR platform. Gynecol Oncol 112:
55–59.
48. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A
(2011) Analysis of Circulating MicroRNA: Preanalytical and Analytical
Challenges. Clinical chemistry 57: 833–840.
49. Adachi T, Nakanishi M, Otsuka Y, Nishimura K, Hirokawa G, et al. (2010)
Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clin
Chem 56: 1183–1185.
50. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, et al. (2010)
Circulating microRNAs in patients with coronary artery disease. Circ Res 107:
677–684.
51. Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, et al. (2009) Plasma
miR-208 as a biomarker of myocardial injury. Clin Chem 55: 1944–1949.
52. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, et al. (2009)
MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues
in mice. Science 324: 1710–1713.
53. Suarez Y, Fernandez-Hernando C, Yu J, Gerber SA, Harrison KD, et al. (2008)
Dicer-dependent endothelial microRNAs are necessary for postnatal angiogen-
esis. Proc Natl Acad Sci U S A 105: 14082–14087.
Haemolysis Alters miRNA Content of Plasma
PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24145